Want to join the conversation?
Biopharmaceutical company $AMGN said that the European Commission has approved the use of IMLYGIC (talimogene laherparepvec) drug for the treatment of unresectable melanoma, a type of skin cancer, in adults. In the study, patients with Stage IIIB, IIIC and IVM1a disease achieved an overall response rate of 40.5% when treated with IMLYGIC.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!